Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.
Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.